"The shared content is misleading because it makes representations about the efficacy of Tasigna but fails to communicate any risk information associated with the use of this drug," said the FDA letter
"We have addressed its concerns by taking the direct and immediate action of taking down the widget referenced by the FDA," the company said.
Facebook should be responsible for creating safeguards for the marketing of medications and other health products on its site, said Jeffrey Chester, a privacy advocate
http://www.businessweek.com/idg/2010-08-06/us-fda-warns-pharma-firm-about-facebook-promotion.html
What I thought was especially interesting was how the FDA was concerned about content and the privacy advocate said Facebook should create safeguards.
Of course it makes more sense for the FDA to get involved than Facebook:
ReplyDeleteThe FDA says it may have the first rules on that by the end of the year.
http://www.npr.org/blogs/health/2010/08/12/129160626/facebook-tasigna-novartis-fda-warning-letter